Staar Surgical (STAA) Cash & Equivalents (2010 - 2026)

Staar Surgical's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $131.9 million for Q2 2026.

• Quarterly Cash & Equivalents fell 23.83% year-over-year to $131.9 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $131.9 million (down 23.83% YoY) and the FY2026 annual result came in at $153.2 million, up 6.24% from the prior year.
• Cash & Equivalents was $131.9 million for Q2 2026 at Staar Surgical, down from $153.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $224.0 million in Q1 2024 and bottomed at $86.5 million in Q4 2022.
• A 5-year average of $154.9 million and a median of $164.0 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 56.7% — and 2024, when it soared 149.0%.
• Staar Surgical's Cash & Equivalents stood at $86.5 million in 2022, then jumped by 111.65% to $183.0 million in 2023, then declined by 21.24% to $144.2 million in 2024, then gained by 22.19% to $176.2 million in 2025, then decreased by 25.14% to $131.9 million in 2026.
• Business Quant data shows STAA's Cash & Equivalents at $131.9 million in Q2 2026, $153.2 million in Q1 2026, and $176.2 million in Q3 2025.